SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

$DOG.X is trending as a Bitcoin-native meme coin launched via the Runes protocol, generating buzz for its fair distribution and strong community. Discussions highlight its potential to drive utility and transaction volume on the Bitcoin network, with many touting it as a leader in the current cycle. Community members are actively promoting its unique position compared to other meme coins and speculating about potential exchange listings.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is trending amid speculation around a potential licensing deal with AstraZeneca, with community members discussing the impact of recent trial data and a possible buyout. Some investors are analyzing trial endpoints and revenue potential, while others are comparing SMMT to competitors like IOVA. The community is closely watching for further developments and official announcements.

ProShares Trust - ProShares Short Dow30 -1x Shares

ProShares Short Dow30

ProShares Short Dow30 ($DOG) is trending as community members highlight its potential as the 'meme face of Bitcoin'. Many view $DOG as more than just a memecoin, emphasizing its fair launch, community ownership, and listing on major crypto exchanges. The 'cult-like army' backing the coin and its potential to mirror $SHIB's success on ETH are also driving interest.

DOVU

DOVU.X is trending as the community highlights its staking rewards and potential in the Real World Asset (RWA) space, particularly due to its "Trust Operating System." Recent news around partnerships and deals related to carbon credits and ecological projects may be acting as a catalyst. Community members are actively discussing its association with Hedera and potential for significant growth.

Gyrodyne LLC engages in the management of a portfolio of medical office and industrial properties. Its properties include Flowerfield, Port Jefferson Professional Park, Courtland Medical Center, and Grove. The company was founded by Peter James Papadakos in 1946 and is headquartered in St. James, NY.

Gyrodyne LLC

GYRO is trending due to a significant land sale agreement, potentially boosting its NAV. The community is discussing the stock's low float and potential for a substantial price increase, with some highlighting potential squeeze dynamics. Bullish sentiment appears to be building, driven by the company's real estate assets and upcoming shareholder meeting.

The Children's Place, Inc. engages in the provision of apparel, footwear, accessories, and other items for children. The firm also designs contracts to manufacture and sell fashionable and value-priced merchandise under the brand names of The Children’s Place, Baby Place, and Gymboree. It operates through The Children’s Place U.S. and The Children’s Place International segments. The Children’s Place U.S. segment refers to the company’s U.S. and Puerto Rico-based stores and revenue from its U.S. based wholesale business. The Children’s Place International segment is involved in the Canadian-based stores, revenue from the company’s Canadian-based wholesale business, as well as revenue from international franchisees. The company was founded by David Pulver and Clinton A. Clark in 1969 and is headquartered in Secaucus, NJ.

Childrens Place Inc

Children's Place is trending due to recent earnings and guidance, with discussions centered on a potential short squeeze given its high short interest. Community members are debating the company's turnaround efforts and the impact of new management, with some highlighting positive comparable DTC sales and others expressing concerns about financials and potential bankruptcy. The stock's low float and high short interest are fueling speculation about a significant price movement.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

NTLA is trending amid discussions about its gene therapy pipeline and recent safety data from a Phase 3 trial; the community is weighing the long-term potential against short-term risks. Some traders are focusing on analyst ratings and potential for a sector rotation, while others discuss potential acquisition scenarios and ARK Invest's position in the stock. Overall, the conversation revolves around the balance between gene editing's promise and the volatility of clinical trials.

Voyager Technologies, Inc. engages in the defense technology and space solutions. It operates through the following segments: Defense & National Security, Space Solutions, and Starlab Space Stations. The Defense & National Security segment consists of innovative mission-critical solutions to protect dynamic and contested domains. The Space Solutions segment consists of space infrastructure, advanced space technology, science systems and mission services. The Starlab Space Stations segment consists of a commercial space station. The company was founded by Dylan Taylor and Matthew Kuta on August 15, 2019 and is headquartered in Denver, CO.

Voyager Technologies Inc. - Ordinary Shares - Class A

Voyager Technologies Inc

VOYG is trending as investors are digesting the implications of its recent inclusion in the Russell 2000 Index and various analyst ratings. The community is actively discussing the company's potential in the defense and space sectors, particularly its connections to initiatives like Golden Dome and partnerships with companies like Palantir. While some see long-term potential, others express concerns about the stock's performance since its IPO and its current valuation.

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Abbvie Inc

ABBV is trending as community members discuss its potential moves in the psychedelic drug space following a recent acquisition, with some suggesting further buyouts of companies like ATAI and CYBN. Also under discussion is AbbVie's oncology pipeline, particularly the potential acquisition of $SLS, driven by promising GPS immunotherapy data. Bullish sentiment is further fueled by updated ratings and price targets from analysts.

Chewy, Inc. operates as an online retailer of pet food and other pet-related products and services. It supplies pet medications, food, treats and other pet-health products and services for dogs, cats, fish, birds, small pets, horses, and reptiles. It has a portfolio of pet healthcare offerings that includes Chewy Pharmacy, Connect with a Vet, and CarePlus, an exclusive suite of pet-first insurance and wellness plans. The company was founded by Ryan Cohen and Michael Day in September 2011 and is headquartered in Plantation, FL.

Chewy Inc - Ordinary Shares - Class A

Chewy Inc

Chewy is trending as investors digest the latest earnings report and guidance, with community members actively discussing the company's market position and future growth prospects. While some express disappointment, others point to positive aspects of the report and reiterate long-term bullish sentiment, viewing any price drops as buying opportunities. Technical analysis and analyst ratings are also contributing to the ongoing conversation around $CHWY.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is ICF International (ICFI) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is ICF International (ICFI) a Great Value Stock Right Now?

ICF International Stock Rises 5.4% Since Q2 Earnings Beat

ICFI beats on Q2 earnings but misses revenues as federal government contracts shrink. Shares rally 5.4% post-earnings.

Here's What Key Metrics Tell Us About ICF (ICFI) Q2 Earnings

The headline numbers for ICF (ICFI) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

ICF International (ICFI) Beats Q2 Earnings Estimates

ICF (ICFI) delivered earnings and revenue surprises of +1.84% and -0.45%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

ICF to Support Hurricane Helene Recovery Across Carolinas

ICF to Support Hurricane Helene Recovery Across Carolinas ICF to Support Hurricane Helene Recovery Across Carolinas PR Newswire RESTON, Va., Jan. 23, 2025 Advanced Technology and Local Expertise to...

ICF Announces Timing of Fourth Quarter and Full Year 2024 Earnings Release and Conference Call

ICF Announces Timing of Fourth Quarter and Full Year 2024 Earnings Release and Conference Call ICF Announces Timing of Fourth Quarter and Full Year 2024 Earnings Release and Conference Call PR...

DHS Awards ICF New $40M Digital Engagement Task Order

DHS Awards ICF New $40M Digital Engagement Task Order DHS Awards ICF New $40M Digital Engagement Task Order PR Newswire RESTON, Va., Jan. 13, 2025 Collaboration Will Enhance Strategic and Digital...

ICF Acquires Applied Energy Group from Ameresco, Inc.

ICF Acquires Applied Energy Group from Ameresco, Inc. ICF Acquires Applied Energy Group from Ameresco, Inc. PR Newswire RESTON, Va. and FRAMINGHAM, Mass., Jan. 7, 2025 Accretive Transaction of...

ICF Awarded Over $40 Million In Contracts to Drive Health Innovation with Advanced Technology

ICF Awarded Over $40 Million In Contracts to Drive Health Innovation with Advanced Technology ICF Awarded Over $40 Million In Contracts to Drive Health Innovation with Advanced Technology PR Newswire...

ICF International, Inc. engages in the provision of professional services and technology-based solutions to government and commercial clients, including management, marketing, technology, and policy consulting and implementation services. The company was founded in 1969 and is headquartered in Reston, VA.

Current Price	$95.21
Prev Close	$94.18
Open	$94.39
Dividend Yield	0.47%
50-Day Moving Average	$91.07
Beta	0.46
Avg. Volume	212,338.24
PE Ratio	16.55

52-Week High	$179.67
52-Week Low	$75.91
Market Capitalization	$1.75B
EPS (Annual)	$5.82
Price to Book	1.75
Revenue Per Employee	$217,181.40
Enterprise Value/EBITDA	N/A

ICFI
ICF International, Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ICFI News

ICFI ICF International, Inc